New Co-Principal Investigators Step Up to Lead Emory Clinical Trials Unit

Emory University plays an important role in antiviral research, especially in the field of HIV/AIDS. In 2020, the National Institutes of Health (NIH) selected the Emory Clinical Trials Unit (CTU) as one of 37 CTUs responsible for implementing the scientific agenda of the NIH HIV/AIDS clinical research network. At the time, The Emory HIV Clinical Trials Unit (CTU) included two Clinical Research Sites in Atlanta that have been part of the CTU for many years: The Ponce de Leon Center and the Hope Clinic of the Emory Vaccine Center and will add two new international sites in Dasmariñas City, Philippines and Mexico City, Mexico.

For the first three years of the project, principal investigators Jeffrey Lennox, M.D., professor of medicine in infectious diseases and associate dean for clinical research at Emory School of Medicine, and Carlos del Rio, M.D., professor of medicine in infectious diseases and interim dean of Emory School of Medicine, have overseen clinical trials conducted at five research sites across three continents. Effective June 1, Lennox and del Rio are stepping down from their roles as co-principal investigators to become CTU investigators and Directors Emeriti of the CTU and two new clinical researchers are assuming leadership of the CTU moving forward.